Hecht Beth sold $134K of XERS
Hecht Beth (See Remarks) sold 16,666 shares of Xeris Biopharma Holdings, Inc. (XERS) at $8.03 ($0.13M total) on 2026-07-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the disclosed open-market sale amount, price, and confirmation of a pre-arranged 10b5-1 plan; it informs positioning/sentiment but not fundamentals.
Market read
Traders may monitor for follow-on insider activity, but this single 10b5-1 sale is typically not a standalone trading catalyst.
What to watch
Insider-sale impact depends on whether there are repeated sales, relative to prior filings, and whether the insider’s remaining stake changes materially—details not provided beyond post-transaction holdings.
Background
The article is an SEC Form 4 insider transaction disclosure for Xeris Biopharma Holdings, Inc.
Ticker impact
SEC Form 4 shows officer Hecht Beth sold 16,666 XERS shares on 2026-07-01 under a pre-arranged 10b5-1 plan.
Low near-term impact; any reaction is likely muted given the stated 10b5-1 pre-arranged plan.
The filing provides transaction size, price, and 10b5-1 context, but no new company performance, guidance, or regulatory/operational event.
Market effects
No sector read-through; this is company-specific insider transaction data.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may not signal bearish expectations; traders may discount it.
Key entities
- issuerXeris Biopharma Holdings, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderHecht Beth
Officer who sold 16,666 shares on 2026-07-01 under a 10b5-1 plan.
